DFDA

Dehydroepiandrosterone (DHEA)

Treatment for Addisons Disease

Typical Dosage: 25-50 mg daily, in the morning

Effectiveness
65%
Safety Score
85%
Clinical Trials
2
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
25-50 mg daily, in the morning
Time to Effect
3-6 months
Treatment Duration
lifetime
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$370
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$616.67
Dehydroepiandrosterone (DHEA) Outcomes

for Addisons Disease

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Common Side Effects
Acne
+8%
Hirsutism
+7%
Oily skin
+6%
Hair loss
+2%

Sources:

nih.gov
endocrine-abstracts.org
the-hospitalist.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Dehydroepiandrosterone (DHEA) in Addisons Disease

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency

NCT00004313COMPLETEDPHASE3
View Study
40 participants
INTERVENTIONAL
Started: Aug 1, 1995

Survey in Patients With Chronic Adrenal Insufficiency in Germany

NCT00444119COMPLETED
View Study
OBSERVATIONAL
Berlin, Germany +1 more
Started: May 1, 2004